Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Feb 10, 2022 5:12pm
140 Views
Post# 34418256

RE:Lower SP Holdings

RE:Lower SP Holdings

It looks like Soleus is accumulating quite a bit.


https://fintel.io/so/us/thtx/soleus-capital-master-fund-l-p



SPCEO1 wrote: We just filed our ownership position with the SEC. Our holdings have dropped considerably from last year but I never placed any sell orders in TH. We had a client who had a 7 figure amount of shares in his account die a couple of years ago and when his estate settled last year, most of his heirs took the assets to their own money managers. They may still own the stock but Stewardship Partners no longer manages those assets so it is not in our totals any longer. We also lost some other accounts over the last year which accounts for the rest of the decline in our ownership. 

We still own just under 4 million shares and are hoping this investment will finally start paying off for our clients (or paying off again might be a better way to put it).  

Other money manager should be reporting their holdings soon so it will be interesting to see what shows up. AIGH reduced their holdings slightly in the fourth quarter but most other hodlers have yet to report.

 

<< Previous
Bullboard Posts
Next >>